Product
Sovateltide
Aliases
IRL-1620, PMZ 1620, PMZ-1620, Tycamzzi™ (1 other aliases)
3 clinical trials
5 indications
Indication
Acute Ischemic StrokeIndication
StrokeIndication
Hypoxic-Ischemic EncephalopathyIndication
Neonatal AsphyxiaIndication
Neonatal EncephalopathyClinical trial
A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic StrokeStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase-II Trial to Assess Safety, and Efficacy of Sovateltide in the Treatment of Hypoxic-ischemic Encephalopathy in NeonatesStatus: Recruiting, Estimated PCD: 2024-11-01